Bharat Biotech receives DCGI approval for Phase 3 clinical trials of its Intra-Nasal vaccine, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Intra nasal vaccines are easier to administer in mass immunization campaigns and can also help in stopping the transmission of the virus. The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country., Intra nasal vaccines are easier to administer in mass immunization campaigns and can also help in stopping the transmission of the virus. The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country., , Read More